Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma-Reference-Cited by-同舟云学术

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

Published:2017-11 Issue: Volume:86 Page:37-45
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hamid Omid,Puzanov Igor,Dummer Reinhard,Schachter Jacob,Daud Adil,Schadendorf Dirk,Blank Christian,Cranmer Lee D.,Robert Caroline,Pavlick Anna C.,Gonzalez Rene,Hodi F. Stephen,Ascierto Paolo A.,Salama April K.S.,Margolin Kim A.,Gangadhar Tara C.,Wei Ziwen,Ebbinghaus Scot,Ibrahim Nageatte,Ribas Antoni

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Targeting oncogenic drivers and the immune system in melanoma;McArthur;J Clin Oncol,2013

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

4. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib;Sosman;N Engl J Med,2012

5. Enhancement of antitumor immunity by CTLA-4 blockade;Leach;Science,1996

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Rare Presentation of Malignant Melanoma of the Face: A Case Report;Cureus;2024-07-18

2. The efficacy outcomes in non-small cell lung cancer patients treated with PD axis inhibitor agents - a population-based study of the Vojvodina region;Pathology and Oncology Research;2024-07-12

3. Tazarotene-induced Gene 1 Induces Melanoma Cell Death by Triggering Endoplasmic Reticulum Stress Response;Frontiers in Bioscience-Landmark;2024-06-24

4. Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy;The Oncologist;2024-05-20

5. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis;Frontiers in Oncology;2024-05-02